Athersys, Inc. (NASDAQ:ATHX) fell 1.6% on Tuesday . The stock traded as low as $2.40 and last traded at $2.49. 10,650 shares traded hands during trading, a decline of 99% from the average session volume of 1,264,315 shares. The stock had previously closed at $2.53.
Several research firms recently weighed in on ATHX. ValuEngine lowered shares of Athersys from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Maxim Group began coverage on shares of Athersys in a research note on Monday, April 23rd. They set a “buy” rating and a $6.00 price objective on the stock. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Tuesday, April 17th. Finally, BidaskClub upgraded shares of Athersys from a “hold” rating to a “buy” rating in a research note on Saturday, May 19th.
The company has a market capitalization of $336.62 million, a price-to-earnings ratio of -8.07 and a beta of -0.79.
Athersys (NASDAQ:ATHX) last released its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.17 million. Athersys had a negative net margin of 1,112.74% and a negative return on equity of 119.58%. analysts expect that Athersys, Inc. will post -0.24 earnings per share for the current year.
In other Athersys news, insider William Lehmann, Jr. sold 14,000 shares of the company’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $1.89, for a total value of $26,460.00. Following the completion of the transaction, the insider now owns 481,973 shares in the company, valued at approximately $910,928.97. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP John J. Harrington sold 15,000 shares of the company’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $1.84, for a total transaction of $27,600.00. The disclosure for this sale can be found here. 18.60% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in Athersys in the 4th quarter worth about $108,000. JPMorgan Chase & Co. grew its position in Athersys by 214.9% in the 1st quarter. JPMorgan Chase & Co. now owns 69,370 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 47,339 shares during the last quarter. Finally, Northern Trust Corp grew its position in Athersys by 7.1% in the 1st quarter. Northern Trust Corp now owns 1,215,690 shares of the biopharmaceutical company’s stock worth $2,225,000 after purchasing an additional 80,708 shares during the last quarter. Hedge funds and other institutional investors own 16.87% of the company’s stock.
Athersys Company Profile
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.